Prothena Shares Plummet Amid Governance Updates
By ATTN Desk · Editorial oversight: Sean Han
PROTHENA CORP PLC (NASDAQ: PRTA)
Introduction
PROTHENA CORP PLC (“Prothena”) is a clinical-stage biotechnology company headquartered in Dublin, Ireland. Founded in December 2012 following a spin-out from Elan Corporation, Prothena focuses on developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases. As of May 27, 2025, shares traded on the Nasdaq Global Select Market at USD 4.89, representing a decrease of 25.68% with a trading volume of 4,145,791.
Corporate Structure and Experience
- Founded: December 2012 (spin-out from Elan Corporation)
- Headquarters: Dublin, Ireland
- Industry: Biotechnology Research
- Employees: 51–200
- Scientific Legacy:
- Athena Neurosciences (est. 1986) made significant discoveries in amyloid biology and related enzymes (gamma secretase, beta secretase).
- Development of natalizumab (Tysabri®) before Athena’s acquisition by Elan in 1996.
Recent Developments and News
- 2025-05-15: Schedule 13G/A filed (CIK 0001559053) reporting Todd W. Fennell’s beneficial ownership of 4,590,805 ordinary shares (8.5% of class).
- 2025-05-16: Form 8-K (items 5.02, 5.07, 9.01) filed to report executive appointments, director nominations, and certain financial commitments.
- 2025-05-23: Form 8-K (items 8.01, 9.01) filed to disclose material events and updates on corporate governance matters.
- 2025-05-27: Shares opened at USD 4.76, reaching a daily low of USD 4.63 and a high of USD 5.35, with trading volume over 4.1 million shares.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Market Cap (intraday) | USD 263.2 M |
| 52-Week Range | 4.63 – 25.42 |
| Volume (Avg.) | 958,728 |
| Revenue (TTM) | USD 137.94 M |
| Net Income (TTM) | –USD 110.27 M |
| EPS (TTM) | –2.05 |
| Price/Sales (TTM) | 2.57 |
| Price/Book (MRQ) | 0.81 |
| Cash & Equivalents (MRQ) | USD 417.94 M |
| Total Debt/Equity (MRQ) | 2.33% |
| Profit Margin | –79.94% |
| Return on Assets (TTM) | –15.49% |
| Return on Equity (TTM) | –23.46% |
Pipeline and Partnerships
- PRX012 and PRX123 (Aβ-tau dual vaccine) for Alzheimer’s disease (wholly owned).
- Prasinezumab (α-synuclein) with Roche for Parkinson’s disease.
- Coramitug (PRX004) with Novo Nordisk for ATTR amyloidosis.
- BMS-986446 (tau) and PRX019 (undisclosed target) with Bristol Myers Squibb for neurodegenerative diseases.
All programs are investigational and have not been approved by the FDA or EMA.
Market Position and Industry Context
- Sector Focus: Neurodegeneration and amyloid pathology, areas with high unmet medical need.
- Competitive Landscape: Companies such as Biogen, Eli Lilly, and Roche are also developing anti-amyloid and anti-tau therapies.
- Volatility Profile: Beta (5-year) of 0.10 indicates lower sensitivity to overall market movements.
- Key Drivers: Clinical trial outcomes, regulatory feedback, and partnership progress are significant factors that will influence valuation and analyst estimates (1-year target of USD 26.86 as per Yahoo Finance).
TL;DR
- Shares declined 25.68% to USD 4.89 on May 27, 2025, with over 4.1 million shares traded.
- The May 15 filing indicates a new 8.5% ownership stake by Todd W. Fennell; May 16 and May 23 filings provide updates on governance.
- Market cap approximately USD 263 million; TTM revenue of USD 138 million versus a net loss of USD 110 million.
- The pipeline in Alzheimer’s, Parkinson’s, and amyloidosis remains under investigation; future developments depend on clinical data and regulatory milestones.